We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Pair Acts in Tandem to Drive Aggressive Brain Cancer Growth

By LabMedica International staff writers
Posted on 09 May 2016
Print article
Image: A photomicrograph of human brain tumor stem cells expressing the OSMR gene (green) (Photo courtesy of Dr. Arezu Jahani-Asl, McGill University).
Image: A photomicrograph of human brain tumor stem cells expressing the OSMR gene (green) (Photo courtesy of Dr. Arezu Jahani-Asl, McGill University).
A pair of genes has been identified that work in tandem to drive the growth and development of the glioblastoma multiforme (GBM) type of aggressive brain tumor.

This form of brain cancer is the most common primary tumor of the central nervous system and is almost always fatal. The aggressive invasion of GBM cells into the surrounding normal brain makes complete surgical removal impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Median survival for newly diagnosed GBM is 14.6 months and declines to eight months for patients with recurrent GBM.

Investigators at McGill University (Montreal, Canada), the Harvard University Medical School (Boston, MA, USA) and the Washington University School of Medicine (St. Louis, MO, USA) were searching for genes that would complement the activity of EGFR (epidermal growth factor receptor)vIII, which was known to produce an important tumor-forming protein in glioblastoma. However, disabling EGFRvIII had not been found to be effective in blocking growth of GBM.

The investigators reported in the April 25, 2016, online edition of the journal Nature Neuroscience that they had identified the cytokine receptor OSMR (oncostatin M receptor) as a direct target gene of the transcription factor STAT3 in mouse astrocytes and human brain tumor stem cells, and that OSMR functioned as an essential co-receptor for EGFRvIII.

The cellular transcription factor STAT3 (signal transducer and activator of transcription 3) is a member of the STAT protein family, which regulates many aspects of cell growth, survival, and differentiation. Malfunction of this signaling pathway is frequently observed in primary tumors and leads to increased angiogenesis and enhanced tumor survival.

The investigators found that OSMR formed a physical complex with EGFRvIII and that depletion of OSMR impaired EGFRvIII-STAT3 signaling. Conversely, drugs that inhibited EGFRvIII phosphorylation also inhibited the EGFRvIII-OSMR interaction and activation of STAT3. EGFRvIII-OSMR signaling in tumors operated constitutively, whereas EGFR-OSMR signaling in normal cells was synergistically activated by the ligands EGF and OSM.

Genetic knockdown of OSMR strongly suppressed mouse glioblastoma cell proliferation and tumor growth as well as growth of human brain tumor stem cell xenografts in mice, and prolonged the lifespan of these animals.

“The discovery has important clinical implications,” said senior author Dr. Azad Bonni, professor of neurobiology at the Washington University School of Medicine. “It provides a new therapeutic avenue for treating this devastating disease, though developing any effective therapy targeting human patients could be years of work.”

Related Links:
McGill University
Harvard University Medical School
Washington University School of Medicine
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.